Department of Orthopedic Surgery, Malatya Training and Research Hospital, Malatya, Turkey.
Department of Orthopedic Surgery, Bursa Kestel State Hospital, Bursa, Turkey.
Med Sci Monit. 2021 Feb 6;27:e928759. doi: 10.12659/MSM.928759.
BACKGROUND Despite increased experience and technical developments in total knee arthroplasty (TKA), chronic postsurgical pain (CPSP) remains one of physicians' biggest challenges. The aim of the present study was to evaluate the effectiveness of perineural injection therapy (PIT) in the management of CPSP after TKA. MATERIAL AND METHODS A total of 60 patients who had been surgically treated with TKA because of advanced knee osteoarthritis was included in the present study. The study included 2 groups. Group A consisted of patients who received 3 rounds of PIT combined with standard postoperative TKA protocol during the same period. Group B received standard postoperative TKA protocols (rehabilitation programs, oral and intravenous analgesics). Clinical effectiveness was evaluated via Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Visual Analog Scale (VAS) at baseline and 1-, 3-, and 6-month follow-ups. RESULTS All repeated measures showed significant improvements (P<0.001) in both groups for VAS and WOMAC scores. These scores were significantly better in group A in all follow-up periods compared with group B (P<0.001). Twenty-nine patients (93.5%) in group A reported excellent or good outcomes compared with 26 patients (89.6%) in group B. CONCLUSIONS PIT is a promising approach in CPSP with minimal cost, simple and secure injection procedures, minimal side effects, and higher clinical efficacy.
尽管全膝关节置换术(TKA)的经验和技术不断发展,但慢性术后疼痛(CPSP)仍然是医生面临的最大挑战之一。本研究旨在评估神经周围注射疗法(PIT)在 TKA 后 CPSP 管理中的有效性。
本研究共纳入 60 例因晚期膝关节骨关节炎接受 TKA 手术治疗的患者。研究包括 2 组。A 组患者在同一时期接受 3 轮 PIT 联合标准术后 TKA 方案。B 组接受标准术后 TKA 方案(康复计划、口服和静脉镇痛剂)。通过 Western Ontario 和 McMaster 大学关节炎指数(WOMAC)和视觉模拟量表(VAS)在基线和 1、3 和 6 个月随访时评估临床疗效。
两组的 VAS 和 WOMAC 评分均显示出明显的改善(P<0.001)。在所有随访期间,A 组的评分均明显优于 B 组(P<0.001)。A 组 29 例(93.5%)患者报告疗效优异或良好,而 B 组 26 例(89.6%)患者报告疗效优异或良好。
PIT 是一种有前途的 CPSP 治疗方法,具有成本低、注射程序简单安全、副作用小、临床疗效高的优点。